Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
Interview of SOM Biotech for Labiotech.eu
Dr. Raúl Insa, SOM Biotech CEO, gave an interview to Labiotech.eu, leading digital media covering […]
SOM Biotech will attend the 12th Annual Global Discovery to Development Innovation Forum (GDDIF)
Dr. Luca Signorile, Senior computational chemist at SOM Biotech, will be attending the 12th Annual […]
SOM Biotech at TechShare – pre-IPO programme launched by Euronext
Dr. Raúl Insa, SOM Biotech CEO, attended the second campus of the 2018-2019 TechShare programme organized by Euronext and Nova […]
3rd Annual Clinical Trials Summit (CTS) 2019
Dr. Santiago Esteva, Head of Clinical Operations at SOM Biotech, will be presenting at the […]
SOMCT02 Huntington’s disease trial recruits 100% of patient target
On March 8, 2019, the SOMCT02 clinical trial successfully closed recruitment, marking 100% fulfillment of […]
SOM Biotech closes a financing round of 7M Euros
SOM Biotech has just closed a financing round of 7 million euros led by a […]
Rare Disease Day 2019
Today, February 28th, is Rare Disease Day, and SOM Biotech is one with Eurordis in […]
Drug Repurposing for Rare Diseases Conference 2019
Findacure‘s Drug Repurposing for Rare Diseases Conference is returning for its sixth consecutive year on […]
SOM Biotech renews collaboration with Biotechnology Business Institute
With the opening of the Postgraduate programs of Biotechnology Business Institute for the school year 2019, SOM […]